Stoboclo® (denosumab-bmwo) – New biosimilar approval
March 3, 2025, Celltrion announced the FDA approval of Stoboclo (denosumab-bmwo), biosimilar to Amgen’s Prolia® (denosumab).
March 3, 2025, Celltrion announced the FDA approval of Stoboclo (denosumab-bmwo), biosimilar to Amgen’s Prolia® (denosumab).